{"id":"oxcarbazepine-xr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Ataxia"},{"rate":"2-5","effect":"Hyponatremia"},{"rate":"1-3","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1068","moleculeType":"Small molecule","molecularWeight":"252.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxcarbazepine is a prodrug that is metabolized to its active metabolite, which selectively blocks voltage-gated sodium channels in their inactive state, stabilizing neuronal membranes and reducing repetitive firing. This mechanism reduces the propagation of seizure activity across neural networks. The extended-release formulation provides sustained drug levels with once-daily dosing.","oneSentence":"Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:05.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (monotherapy and adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03374709","phase":"PHASE4","title":"Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2018-12-14","conditions":"Trigeminal Neuralgia","enrollment":""},{"nctId":"NCT03567681","phase":"PHASE4","title":"Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression","status":"UNKNOWN","sponsor":"Collaborative Care Initiative, LLC","startDate":"2018-06-13","conditions":"Bipolar Depression, Treatment Effectiveness, Measure-based Guidance","enrollment":120},{"nctId":"NCT00918047","phase":"PHASE1","title":"Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Epilepsies, Partial","enrollment":18},{"nctId":"NCT00908349","phase":"PHASE3","title":"Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Partial Epilepsy","enrollment":214},{"nctId":"NCT00918424","phase":"","title":"Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects","status":"APPROVED_FOR_MARKETING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT00772603","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2008-11","conditions":"Epilepsies, Partial","enrollment":366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SPN-804O","Oxtellar XR"],"phase":"phase_3","status":"active","brandName":"Oxcarbazepine XR","genericName":"Oxcarbazepine XR","companyName":"Supernus Pharmaceuticals, Inc.","companyId":"supernus-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures. Used for Partial-onset seizures (monotherapy and adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}